EP0957166A4 - IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas - Google Patents

IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas

Info

Publication number
EP0957166A4
EP0957166A4 EP97937807A EP97937807A EP0957166A4 EP 0957166 A4 EP0957166 A4 EP 0957166A4 EP 97937807 A EP97937807 A EP 97937807A EP 97937807 A EP97937807 A EP 97937807A EP 0957166 A4 EP0957166 A4 EP 0957166A4
Authority
EP
European Patent Office
Prior art keywords
fas ligand
originating
active fragments
inducing apoptosis
humanized immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97937807A
Other languages
German (de)
English (en)
Other versions
EP0957166A1 (fr
Inventor
Ko Okumura
Motomi Nakata
Hirofumi Higuchi
Yoshitaka Ushio
Hiroaki Maeda
Yasuyuki Eda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OKUMURA, KO
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP05023018A priority Critical patent/EP1642908A2/fr
Publication of EP0957166A1 publication Critical patent/EP0957166A1/fr
Publication of EP0957166A4 publication Critical patent/EP0957166A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
EP97937807A 1996-09-02 1997-08-27 IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas Withdrawn EP0957166A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05023018A EP1642908A2 (fr) 1996-09-02 1997-08-27 Région d'induction d'apoptose prenant naissance dans un ligand fas

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP23174296 1996-09-02
JP23174296 1996-09-02
JP27154696 1996-09-20
JP27154696 1996-09-20
PCT/JP1997/002983 WO1998010070A1 (fr) 1996-09-02 1997-08-27 IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05023018A Division EP1642908A2 (fr) 1996-09-02 1997-08-27 Région d'induction d'apoptose prenant naissance dans un ligand fas

Publications (2)

Publication Number Publication Date
EP0957166A1 EP0957166A1 (fr) 1999-11-17
EP0957166A4 true EP0957166A4 (fr) 2004-12-15

Family

ID=26530062

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05023018A Withdrawn EP1642908A2 (fr) 1996-09-02 1997-08-27 Région d'induction d'apoptose prenant naissance dans un ligand fas
EP97937807A Withdrawn EP0957166A4 (fr) 1996-09-02 1997-08-27 IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05023018A Withdrawn EP1642908A2 (fr) 1996-09-02 1997-08-27 Région d'induction d'apoptose prenant naissance dans un ligand fas

Country Status (5)

Country Link
US (1) US6777540B1 (fr)
EP (2) EP1642908A2 (fr)
AU (1) AU725329B2 (fr)
CA (1) CA2264968A1 (fr)
WO (1) WO1998010070A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69932434D1 (de) 1998-05-29 2006-08-31 Mochida Pharm Co Ltd Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
BRPI0317376B8 (pt) 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
CN101155832B (zh) 2005-02-08 2013-02-06 一般财团法人化学及血清疗法研究所 抗体的改良方法
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
PT2101877E (pt) 2006-12-28 2013-07-22 Deutsches Krebsforsch Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo
CN101918449A (zh) * 2007-12-12 2010-12-15 平切尔有限责任公司 用于天疱疮的含有抗Fas配体抗体的药物
CN101357942B (zh) * 2008-05-30 2012-01-04 中国人民解放军第三军医大学 一种中和肠出血性大肠杆菌0157：H7志贺毒素Ⅱ的单克隆抗体、Fab抗体与应用
TWI466684B (zh) * 2008-06-30 2015-01-01 Morphotek Inc 抗ｇｄ２抗體及其相關方法及用途
WO2010019565A2 (fr) * 2008-08-12 2010-02-18 Medlmmune, Llc Anticorps anti-ephrine b2 et leur utilisation dans le traitement de maladies
KR101769858B1 (ko) 2008-12-12 2017-08-21 핀셀 에스알엘 항 Ｆａｓ 리간드 항체를 함유한 천포창 치료제
JP2013505707A (ja) * 2009-09-25 2013-02-21 上海抗体薬物国家工程研究中心有限公司 コンピュータ支援設計により高親和性の抗体又はタンパク質分子を得る方法
EP3076179A1 (fr) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnostic et traitement de gliomes mal différenciés
WO2017051002A1 (fr) * 2015-09-23 2017-03-30 Apogenix Ag Anticorps anti-cd95l
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007861A1 (fr) * 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
WO1995013293A1 (fr) * 1993-11-10 1995-05-18 Mochida Pharmaceutical Co., Ltd. Ligand fas, partie de ce dernier, et adn codant pour ce dernier
WO1996029350A1 (fr) * 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. ANTICORPS MONOCLONAL REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas ET SON PROCEDE DE PRODUCTION
EP0842948A1 (fr) * 1995-06-30 1998-05-20 Mochida Pharmaceutical Co., Ltd. ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69535719T2 (de) 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. Fas-antigenbindender ligand
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007861A1 (fr) * 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
WO1995013293A1 (fr) * 1993-11-10 1995-05-18 Mochida Pharmaceutical Co., Ltd. Ligand fas, partie de ce dernier, et adn codant pour ce dernier
EP0675200A1 (fr) * 1993-11-10 1995-10-04 Mochida Pharmaceutical Co., Ltd. Un ligand de FAS, un fragment de celui-ci et ADN l'encodant
WO1996029350A1 (fr) * 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. ANTICORPS MONOCLONAL REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas ET SON PROCEDE DE PRODUCTION
EP0872488A1 (fr) * 1995-03-20 1998-10-21 Sumitomo Electric Industries, Ltd. ANTICORPS MONOCLONAL REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas ET SON PROCEDE DE PRODUCTION
EP0842948A1 (fr) * 1995-06-30 1998-05-20 Mochida Pharmaceutical Co., Ltd. ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAYAGAKI: "Metalloproteinase-mediated release of human fas ligand", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 182, 1 December 1995 (1995-12-01), pages 1777 - 1783, XP002096854, ISSN: 0022-1007 *
See also references of WO9810070A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8221749B2 (en) 2008-02-20 2012-07-17 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Also Published As

Publication number Publication date
US6777540B1 (en) 2004-08-17
EP1642908A2 (fr) 2006-04-05
EP0957166A1 (fr) 1999-11-17
AU725329B2 (en) 2000-10-12
WO1998010070A1 (fr) 1998-03-12
AU4030797A (en) 1998-03-26
CA2264968A1 (fr) 1998-03-12

Similar Documents

Publication Publication Date Title
EP0957166A4 (fr) IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas
EP1071458A4 (fr) Anticorps humanises et utilisations correspondantes
SG48420A1 (en) Humanized antibodies and uses thereof
HUP0003513A3 (en) Monoclonal antibody inducing apoptosis
EP0766815A4 (fr) Detecteur de glace et de liquide
EP0805161A4 (fr) Proteine fixant le (1-3)-beta-d-glucane, anticorps reconnaissant la proteine et utilisation de la proteine et de l'anticorps
GB9503661D0 (en) Antenna and radiotelephone using the same
IL120553A0 (en) Recombinant antibodies directed against FAS and DNA coding therefor
HUP9800613A3 (en) Humanized antibody against human fas-antigene
EP0704458A3 (fr) Anticorps contre le collagène du type IV et leur utilisation
ZA9510195B (en) Monoclonal antibody fragments having immunosuppressant activity
EP0977590A4 (fr) Anticorps monoclonaux humains
IL113725A0 (en) Preparing recombinant aprotini and its variants
TW467467U (en) High-frequency detecting elements and high-frequency heater using the same
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
AP9500732A0 (en) Anti viral and anti cancer agents
SI1068241T1 (sl) Protitelesne variante in njihovi fragmenti
GB9423267D0 (en) Compounding elements and use thereof
KR950033940U (ko) 냉장고 및 온장고의 음료수 유출장치
KR960000572U (ko) 연속고추분쇄장치
GB2279142B (en) Heat reflective and/or heat absorbent material
ZA9610336B (en) Anti-cd6 monoclonal antibodies and their uses
KR950014814U (ko) 예열용 벤드 히터(band heater)
PL329866A1 (en) Monoclonal antibody against human mp52
GB9402593D0 (en) Antibody fragments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE ES FR GB IT LI NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OKUMURA, KO

A4 Supplementary search report drawn up and despatched

Effective date: 20041029

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/395 B

Ipc: 7C 12N 15/13 B

Ipc: 7C 07K 16/28 A

17Q First examination report despatched

Effective date: 20050322

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070123